ESMO 2022 | TUXEDO-1: QoL and neurocognitive function in HER2-positive BC w/ brain metastasis treated with T-DXd

Name: TUXEDO-1: QoL and neurocognitive function in HER2-positive BC w/ brain metastasis treated with T-DXd
Uploaded: 2022-09-10T00:00:00Z
Duration: 1 min 23 s

Angelika Starzer • 10 Sep 2022

ESMO 2022

Breast Cancer Antibodies Trastuzumab deruxtecan

TUXEDO-1

Angelika Starzer, MD, Medical University of Vienna, Vienna, Austria, provides an overview of quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab deruxtecan in patients enrolled in the Phase II TUXEDO-1 trial (NCT04752059). Quality of life and neurocognitive function were maintained in the TUXEDO-1 trial which supports first-line systemic therapy with trastuzumab deruxtecan in patients with active brain metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.